Drug Trial Radar · NCT04081103
NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries
Last checked: Nov 19, 2026Latest source record: Jul 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
35
Actual
Start
Jun 30, 2020
Primary completion
Feb 7, 2022
Study completion Feb 7, 2022
Sponsor
- Lead sponsor
- Glaukos CorporationIndustry
- Sponsor type
- Industry
- Collaborators
- Amber Ophthalmics, Inc.
- First posted
- Sep 9, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will enroll participants with a non-infected, corneal persistent epithelial defect (PED) resulting from an ocular chemical and/or thermal ocular injury which is non-responsive or refractory to current standard of care for at least 14 days. It will assess the efficacy and safety of Nexagon® (lufepirsen) plus standard of care versus NEXAGON-vehicle (placebo) plus standard of care. The recovery of the corneal epithelium will be the primary outcome measure, defined as a cornea that re-epithelializes by Day 28 of treatment and remains re-epithelialized for at least a further 28 days.
Conditions
- Corneal Persistent Epithelial Defect
Interventions
Nexagon® (lufepirsen) High Dose ConcentrationDrug
Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.
Nexagon® (lufepirsen) Low Dose ConcentrationDrug
Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.
VehicleDrug
Vehicle is administered topically in the affected eye three (3) times over 28 days.
Open-label Nexagon® (lufepirsen)Drug
Open-label Nexagon® (lufepirsen) for participants who do not heal (re-epithelialize) at the end of the 28-day treatment phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Proportion of Subjects Achieving Corneal Epithelial Recovery, as Assessed by Slit Lamp Examination.Time frame: Up to 56 days.
- Incidence of Treatment Emergent Adverse Events as Assessed by CTCAE v 5.0Time frame: Up to 30 days after last application of intervention
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jules Stein Eye Institute
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.